Wound Management Technologies, Inc. Announces Its 2014 Annual Meeting Of Shareholders

ADDISON, TX--(Marketwired - August 26, 2014) - Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX®, announced that its 2014 Annual Meeting of Shareholders will be held at the Company's corporate offices located at 16633 Dallas Parkway, Suite 250 in Addison, TX on September 3, 2014 at 10AM CST.

Wound Management has the record date of July 11, 2014 for the determination of shareholders entitled to notice of and to vote at the Annual Meeting. For shareholders who are unable to attend in person, the Company has provided a dial-in to the meeting, in a listen-only mode. To listen, dial 1-877-407-4018 (US) or 1-201-689-8471 (International) and request Wound Management's 2014 Annual Meeting of Shareholders. A dial-in replay will also be available until October 3, 2014. To access the replay, the dial-in number is 1-877-870-5176 (US) or 1-858-384-5517 (International) with the pin access 13590032.

About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its Wound Care Innovations subsidiary's unique, patented collagen product line, CellerateRX® which is FDA-cleared for all wound types except 3rd degree burns. The wound care products are reimbursable under Medicare Part B and the surgical products are reimbursed as part of a procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.

Information about Forward-Looking Statements
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.